Prescient Therapeutics Limited
PSTTF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$117.53M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $117.53 Million |
|---|---|
| Enterprise Value | - |
| Annual dividend | $0.00 |
| Earnings per Share | $- |
| Beta | 1.05 |
| Outstanding Shares | - |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -9.57 |
|---|---|
| PEG | 25.09 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Prescient Therapeutics Limited
3 employees
CEO: James McDonnell
Prescient Therapeutics Limited (PTX.AX) is an Australian clinical-stage oncology firm dedicated to creating novel therapeutic agents for various cancer types. The company's primary experimental compound, PTX-200, is currently undergoing ...